Lalimos, Luela C.

HRN: 27-53-89  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/27/2025
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
07/27/2025
08/03/2025
IVT
1.5g
Q6
Cellulitis
Checking Initial Appropriateness 
07/27/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
07/27/2025
08/03/2025
IVT
600mg
Q8
Cellulitis
Checking Initial Appropriateness 
08/04/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/04/2025
08/11/2025
IV
250 Mg
OD
Klebsiella Pneumoniae Infection
Checking Initial Appropriateness 
08/04/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/04/2025
08/11/2025
IVTT
250mg
Q 12h
EMPIRIC
Checking Initial Appropriateness 
08/05/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
07/27/2025
08/26/2025
IVTT
600mg
Q8
Cellulitis
Checking Initial Appropriateness 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: